{"entity":{"type":"insider","cik":"0001518010","url":"/insider/0001518010","json_url":"/insider/0001518010.json","name":"Logerfo Michael","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":10,"n_filings":7,"first":"2011-04-20","last":"2014-02-28","span_basis":"filed_date"},"name_variants":[{"name":"Logerfo Michael","source":"filing","n_filings":7,"first_seen":"2011-04-20","last_seen":"2014-02-28"}],"transactions":[{"id":6369505,"accession":"0001181431-14-009951","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-14-009951","line_url":"/filing/0001181431-14-009951#line-1","is_derivative":false,"issuer_cik":"0001369786","issuer_name":"Sagent Pharmaceuticals, Inc.","issuer_ticker":"SGNT","issuer_name_source":null,"issuer_url":"/issuer/0001369786","owner_cik":"0001518010","owner_name":"Logerfo Michael","owner_url":"/insider/0001518010","role":"Officer (Chief Legal Officer)","officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2021.0,"shares_display":"2,021","price_per_share":21.43,"price_display":"21.43","price_state":"stated","total_value":43310.03,"total_display":"43,310.03","shares_owned_after":33011.0,"shares_owned_after_display":"33,011","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-02-27","filed_date":"2014-02-28","scope":"insider"},{"id":6369420,"accession":"0001181431-14-008853","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001181431-14-008853","line_url":"/filing/0001181431-14-008853#line-3","is_derivative":false,"issuer_cik":"0001369786","issuer_name":"Sagent Pharmaceuticals, Inc.","issuer_ticker":"SGNT","issuer_name_source":null,"issuer_url":"/issuer/0001369786","owner_cik":"0001518010","owner_name":"Logerfo Michael","owner_url":"/insider/0001518010","role":"Officer (Chief Legal Officer)","officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4638.0,"shares_display":"4,638","price_per_share":22.05,"price_display":"22.05","price_state":"stated","total_value":102267.9,"total_display":"102,267.90","shares_owned_after":19957.0,"shares_owned_after_display":"19,957","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-02-20","filed_date":"2014-02-24","scope":"insider"},{"id":6369417,"accession":"0001181431-14-008853","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-14-008853","line_url":"/filing/0001181431-14-008853#line-2","is_derivative":false,"issuer_cik":"0001369786","issuer_name":"Sagent Pharmaceuticals, Inc.","issuer_ticker":"SGNT","issuer_name_source":null,"issuer_url":"/issuer/0001369786","owner_cik":"0001518010","owner_name":"Logerfo Michael","owner_url":"/insider/0001518010","role":"Officer (Chief Legal Officer)","officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3894.0,"shares_display":"3,894","price_per_share":21.78,"price_display":"21.78","price_state":"stated","total_value":84811.32,"total_display":"84,811.32","shares_owned_after":36063.0,"shares_owned_after_display":"36,063","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-02-20","filed_date":"2014-02-24","scope":"insider"},{"id":2307677,"accession":"0001181431-12-059585","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-12-059585","line_url":"/filing/0001181431-12-059585#line-2","is_derivative":false,"issuer_cik":"0001369786","issuer_name":"Sagent Pharmaceuticals, Inc.","issuer_ticker":"SGNT","issuer_name_source":null,"issuer_url":"/issuer/0001369786","owner_cik":"0001518010","owner_name":"Logerfo Michael","owner_url":"/insider/0001518010","role":"Officer (Chief Legal Officer)","officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6867.0,"shares_display":"6,867","price_per_share":14.64,"price_display":"14.64","price_state":"stated","total_value":100532.88,"total_display":"100,532.88","shares_owned_after":13615.0,"shares_owned_after_display":"13,615","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-11-19","filed_date":"2012-11-20","scope":"insider"},{"id":2307672,"accession":"0001181431-12-059585","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-12-059585","line_url":"/filing/0001181431-12-059585#line-1","is_derivative":false,"issuer_cik":"0001369786","issuer_name":"Sagent Pharmaceuticals, Inc.","issuer_ticker":"SGNT","issuer_name_source":null,"issuer_url":"/issuer/0001369786","owner_cik":"0001518010","owner_name":"Logerfo Michael","owner_url":"/insider/0001518010","role":"Officer (Chief Legal Officer)","officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2271.0,"shares_display":"2,271","price_per_share":14.68,"price_display":"14.68","price_state":"stated","total_value":33338.28,"total_display":"33,338.28","shares_owned_after":20482.0,"shares_owned_after_display":"20,482","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-11-16","filed_date":"2012-11-20","scope":"insider"},{"id":3376210,"accession":"0001181431-12-058977","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001181431-12-058977","line_url":"/filing/0001181431-12-058977#line-4","is_derivative":false,"issuer_cik":"0001369786","issuer_name":"Sagent Pharmaceuticals, Inc.","issuer_ticker":"SGNT","issuer_name_source":null,"issuer_url":"/issuer/0001369786","owner_cik":"0001518010","owner_name":"Logerfo Michael","owner_url":"/insider/0001518010","role":"Officer (Chief Legal Officer)","officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9000.0,"shares_display":"9,000","price_per_share":14.38,"price_display":"14.38","price_state":"stated","total_value":129420.0,"total_display":"129,420.00","shares_owned_after":22753.0,"shares_owned_after_display":"22,753","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-11-15","filed_date":"2012-11-16","scope":"insider"},{"id":3376205,"accession":"0001181431-12-058977","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-12-058977","line_url":"/filing/0001181431-12-058977#line-2","is_derivative":false,"issuer_cik":"0001369786","issuer_name":"Sagent Pharmaceuticals, Inc.","issuer_ticker":"SGNT","issuer_name_source":null,"issuer_url":"/issuer/0001369786","owner_cik":"0001518010","owner_name":"Logerfo Michael","owner_url":"/insider/0001518010","role":"Officer (Chief Legal Officer)","officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":14.56,"price_display":"14.56","price_state":"stated","total_value":14560.0,"total_display":"14,560.00","shares_owned_after":14415.0,"shares_owned_after_display":"14,415","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-11-14","filed_date":"2012-11-16","scope":"insider"},{"id":2850829,"accession":"0001181431-12-033167","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-12-033167","line_url":"/filing/0001181431-12-033167#line-1","is_derivative":false,"issuer_cik":"0001369786","issuer_name":"Sagent Pharmaceuticals, Inc.","issuer_ticker":"SGNT","issuer_name_source":null,"issuer_url":"/issuer/0001369786","owner_cik":"0001518010","owner_name":"Logerfo Michael","owner_url":"/insider/0001518010","role":"Officer (Chief Legal Officer)","officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7000.0,"shares_display":"7,000","price_per_share":15.86,"price_display":"15.86","price_state":"stated","total_value":111020.0,"total_display":"111,020.00","shares_owned_after":13615.0,"shares_owned_after_display":"13,615","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-05-25","filed_date":"2012-05-29","scope":"insider"},{"id":3303178,"accession":"0001181431-12-031174","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-12-031174","line_url":"/filing/0001181431-12-031174#line-1","is_derivative":false,"issuer_cik":"0001369786","issuer_name":"Sagent Pharmaceuticals, Inc.","issuer_ticker":"SGNT","issuer_name_source":null,"issuer_url":"/issuer/0001369786","owner_cik":"0001518010","owner_name":"Logerfo Michael","owner_url":"/insider/0001518010","role":"Officer (Chief Legal Officer)","officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":15.69,"price_display":"15.69","price_state":"stated","total_value":31380.0,"total_display":"31,380.00","shares_owned_after":20615.0,"shares_owned_after_display":"20,615","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-05-17","filed_date":"2012-05-18","scope":"insider"},{"id":9079644,"accession":"0001181431-11-024765","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-11-024765","line_url":"/filing/0001181431-11-024765#line-1","is_derivative":false,"issuer_cik":"0001369786","issuer_name":"Sagent Holding Co.","issuer_ticker":"SGNT","issuer_name_source":null,"issuer_url":"/issuer/0001369786","owner_cik":"0001518010","owner_name":"Logerfo Michael","owner_url":"/insider/0001518010","role":"Officer (Chief Legal Officer)","officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":16000.0,"total_display":"16,000.00","shares_owned_after":1000.0,"shares_owned_after_display":"1,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-04-20","filed_date":"2011-04-20","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":10,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":8,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":10},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001369786","name":"Sagent Pharmaceuticals, Inc.","url":"/issuer/0001369786","role":"Officer (Chief Legal Officer)","n_filings":7,"first_seen":"2011-04-20","last_seen":"2014-02-28"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001518010","retrieved_at":"2026-08-21T10:18:01+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}